CA3013497A1 - Compositions a penetration elevee et leurs applications - Google Patents

Compositions a penetration elevee et leurs applications Download PDF

Info

Publication number
CA3013497A1
CA3013497A1 CA3013497A CA3013497A CA3013497A1 CA 3013497 A1 CA3013497 A1 CA 3013497A1 CA 3013497 A CA3013497 A CA 3013497A CA 3013497 A CA3013497 A CA 3013497A CA 3013497 A1 CA3013497 A1 CA 3013497A1
Authority
CA
Canada
Prior art keywords
hpc
substituted
group
unsubstituted
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3013497A
Other languages
English (en)
Other versions
CA3013497C (fr
Inventor
Chongxi Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3213470A priority Critical patent/CA3213470A1/fr
Publication of CA3013497A1 publication Critical patent/CA3013497A1/fr
Application granted granted Critical
Publication of CA3013497C publication Critical patent/CA3013497C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/20Polycyclic condensed hydrocarbons
    • C07C15/27Polycyclic condensed hydrocarbons containing three rings
    • C07C15/30Phenanthrenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/20Polycyclic condensed hydrocarbons
    • C07C15/38Polycyclic condensed hydrocarbons containing four rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14[b,f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/227-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)

Abstract

Linvention concerne des compositions à pénétration élevée (HPC) dun composé parent, qui sont capables de traverser des barrières biologiques par pénétration efficace élevée. Les HPC peuvent être tranformées en médicaments parents ou en composés apparentés à des médicaments parents, tels que des métabolites, après passage dune ou plusieurs barrières biologiques, ce qui produit des traitements pour des états que les médicaments parents ou les composés apparentés à des médicaments parents peuvent traiter. Les HPC peuvent également atteindre des zones que leurs médicaments parents ou leurs composés apparentés à des médicaments parents ne peuvent atteindre ou produire une concentration suffisante au niveau des zones cibles HPC de NSAIA. Les HPC ont montré, par exemple des indications telles que le traitement de la chute des cheveux. Une HPC peut être administrée à un sujet via des voies dadministration variées, par exemple, localement à un site daction sur un état à une concentration élevée ou de manière systémique à un sujet biologique et entrer dans la circulation générale plus rapidement.
CA3013497A 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications Active CA3013497C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3213470A CA3213470A1 (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12005208P 2008-12-04 2008-12-04
US61/120,052 2008-12-04
CA2745206A CA2745206C (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2745206A Division CA2745206C (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3213470A Division CA3213470A1 (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Publications (2)

Publication Number Publication Date
CA3013497A1 true CA3013497A1 (fr) 2010-06-10
CA3013497C CA3013497C (fr) 2023-10-31

Family

ID=42233643

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3213470A Pending CA3213470A1 (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications
CA2745206A Active CA2745206C (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications
CA3013497A Active CA3013497C (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA3213470A Pending CA3213470A1 (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications
CA2745206A Active CA2745206C (fr) 2008-12-04 2009-12-04 Compositions a penetration elevee et leurs applications

Country Status (12)

Country Link
US (2) US11541029B2 (fr)
EP (1) EP2370406A4 (fr)
JP (6) JP2012511027A (fr)
KR (6) KR20210123406A (fr)
CN (6) CN113636965A (fr)
AU (2) AU2009322112B2 (fr)
BR (2) BR122021011394B1 (fr)
CA (3) CA3213470A1 (fr)
MX (4) MX337730B (fr)
RU (2) RU2630577C2 (fr)
TW (1) TWI383802B (fr)
WO (1) WO2010065936A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056207A1 (fr) 2006-11-08 2008-05-15 Chongxi Yu Systèmes de libération transdermique de peptides et composés associés
US8389679B2 (en) * 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
EP4067370A1 (fr) * 2009-05-08 2022-10-05 Chongxi Yu Compositions promédicamenteuses à pénétration élevée de peptides et de composés apparentés à des peptides
RU2016115906A (ru) * 2009-06-10 2018-11-28 Текфилдз Байокем Ко., Лтд. Композиции или пролекарства противомикробных и родственных противомикробным соединений, обладающие высокой проникающей способностью
DE102012009057A1 (de) 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
JP6445967B2 (ja) * 2012-05-16 2018-12-26 テックフィールズ ファーマ カンパニー リミテッド 肺疾患の治療のための高浸透性プロドラッグ組成物およびその薬学的組成物
CA3212170A1 (fr) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Nouveaux medicaments a penetration elevee et leurs compositions pour le traitement de maladies de parkinson
CN106572986A (zh) * 2014-03-10 2017-04-19 本杰明·M·余 用于经皮递送的方法和组合物
WO2017147161A1 (fr) * 2016-02-23 2017-08-31 Raju Mohan Traitement de troubles ou d'affections dermatologiques
PL3474858T3 (pl) * 2016-06-28 2022-01-17 Asamedic As Dwuskładnikowa kompozycja zawierająca kwas acetylosalicylowy
CN106916788B (zh) * 2017-04-12 2019-06-25 北京市肿瘤防治研究所 人紫杉醇耐药胃癌细胞hgc-27/ptx及其制备方法
WO2018200859A1 (fr) * 2017-04-26 2018-11-01 Kalman Thomas I Dérivés de nucléoside multicibles
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
CN111566081B (zh) * 2017-11-20 2021-04-06 天津安百胜医疗科技有限公司 一种双酰胺复合物及其制备方法和用途
JP6987104B2 (ja) * 2017-12-28 2021-12-22 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
CN109172580B (zh) * 2018-09-06 2021-04-27 中山万汉制药有限公司 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂
TWI680724B (zh) * 2018-10-09 2020-01-01 兟齊綜合事業有限公司 血壓與血糖調降組合物與一葉草萃取物於製備血壓與血糖調降組合物之用途
IL296626A (en) * 2020-03-20 2022-11-01 Techfields Inc A method for improving the stability of a pharmaceutical preparation containing a highly penetrating drug and a pharmaceutical preparation obtained from it
EP4279131A1 (fr) * 2022-05-20 2023-11-22 Bioithas S.L. Compositions probiotiques pour le traitement de l'alopécie
CN117964029A (zh) * 2024-03-28 2024-05-03 内蒙古莱科作物保护有限公司 基于溴虫腈生产中产生的废液制备对氯苯甘氨酸的方法

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1815802A (en) 1927-02-11 1931-07-21 Ig Farbenindustrie Ag Process for dehydrating vapor mixtures containing acetic anhydride and water
US2671805A (en) 1952-07-02 1954-03-09 Searle & Co Basically substituted o-arylamino-benzamides
GB984471A (en) 1961-01-12 1965-02-24 Parke Davis & Co Anthranilic acid esters and methods for producing the same
BE630053A (fr) 1962-03-27
CH399486A (fr) 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
US3365483A (en) 1963-06-05 1968-01-23 Starogardzkie Zakl Farma Process for obtaining diethylaminoethanol acetylsalicylate hydrochloride
GB1032564A (en) * 1963-10-31 1966-06-08 Bayer Ag Steroid-guanylhydrazones
US3420871A (en) 1964-09-01 1969-01-07 Parke Davis & Co Anthranilic acid esters
FR5342M (fr) 1966-03-08 1967-09-04
US3488380A (en) 1966-03-30 1970-01-06 Bristol Myers Co Carbamate esters and their method of preparation
US3476791A (en) 1966-05-04 1969-11-04 Trustees Of Ohio State Univ Th O-thiocarbamoyl benzoic acid esters
DK121236B (da) 1967-07-03 1971-09-27 Gea As Analogifremgangsmåde til fremstilling af terapeutisk aktive, basisk substituerede amider af N-substituerede antranilsyrer, eller syreadditionssalte deraf.
GB1187259A (en) 1967-10-23 1970-04-08 Hexachimie New Aminoalkyl Esters of 2-Anilino-Nicotinic Acids and process for their manufacture
US4044049A (en) 1968-01-19 1977-08-23 Merck & Co., Inc. Phenyl benzoic acid compounds
FR1593024A (fr) 1968-09-18 1970-05-25
GB1415295A (en) * 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
US3956363A (en) 1969-08-08 1976-05-11 Merck & Co., Inc. Substituted indenyl acetic acids
US3957764A (en) 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
JPS4924911B1 (fr) 1970-12-07 1974-06-26
US3787324A (en) 1971-03-01 1974-01-22 Warner Lambert Co 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,dioxides and process for their production
US3704298A (en) 1971-06-22 1972-11-28 Warner Lambert Co 4-acyloxy-3-(2-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides
US3966923A (en) 1972-06-05 1976-06-29 Pierre Fabre S.A. Medicaments intended for the prevention and treatment of ischemic disturbances
FR2193581B1 (fr) * 1972-07-27 1975-10-17 Fabre Sa Pierre
US4006181A (en) 1972-07-27 1977-02-01 Pierre Fabre S.A. Process for the obtaining of esters of acetylsalicylic acid and amino alcohols
US4035376A (en) 1972-10-24 1977-07-12 Janssen Pharmaceutica N.V. Aroyl-substituted phenylacetic acid derivatives
US4012508A (en) 1975-02-03 1977-03-15 Burton Verna M Topical composition and method
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4150137A (en) * 1975-12-24 1979-04-17 Hisamitsu Pharmaceutical Co. Inc. Pyridylalkyl esters of 2-(p-isobutylphenyl)acetic acid and propionic acids and use
US4192871A (en) * 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
FR2348701A1 (fr) 1976-04-22 1977-11-18 Hexachimie Nouveau derive du p-acetamidophenol,sa preparation et son utilisation en therapeutique
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
US4180665A (en) 1976-06-01 1979-12-25 Ciba-Geigy Aktiengesellschaft Substituted 3-benz(cd)indol-2-(1H)-ylidene-furo[2,3-b]quinoxalin-2(3H)one dyestuffs
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
JPS5446773A (en) 1977-09-22 1979-04-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analog and its preparation
IT1090782B (it) 1977-11-30 1985-06-26 Menarini Sas 2 4 bifenilil 2 dietilamino alchil propionamide suoi sali e procedimenti di fabbricazione relativi
US4206220A (en) 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4244948A (en) 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
US4285951A (en) * 1979-09-07 1981-08-25 Warner-Lambert Company 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent
DE3023206A1 (de) 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS5714589A (en) 1980-06-27 1982-01-25 Mitsui Toatsu Chem Inc Benzothiazine derivative, its preparation and drug composition
JPS57183738A (en) 1981-05-06 1982-11-12 Yamanouchi Pharmaceut Co Ltd Aromatic carboxylic acid derivative
US4543353A (en) 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
JPS594419B2 (ja) * 1982-09-03 1984-01-30 日清製粉株式会社 ピルビン酸アミド誘導体
FR2542998B1 (fr) 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4472431A (en) 1983-08-18 1984-09-18 Methodist Hospital Of Indiana, Inc. Method for treatment of shock
US4640689A (en) 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4551452A (en) 1983-12-21 1985-11-05 Pfizer Inc. Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
EP0152379A3 (fr) 1984-02-15 1986-10-29 Ciba-Geigy Ag Procédé pour la préparation de compositions pharmaceutiques contenant des liposomes unilamellaires
JPS60184077A (ja) 1984-02-23 1985-09-19 フアイザー・インコーポレーテツド 抗炎症性オキシム前駆薬
GB8511988D0 (en) 1985-05-11 1985-06-19 Beecham Group Plc Compounds
US4640911A (en) 1985-05-29 1987-02-03 Ciba-Geigy Corporation Acylated sugar derivatives, processes for their manufacture, and their use
US4623486A (en) 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
US4822773A (en) 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
AU6898287A (en) 1986-01-30 1987-08-25 University Of Utah, The Treatment of bone loss
IT1208736B (it) 1986-03-04 1989-07-10 Sigma Tau Ind Farmaceuti Alogenuri dell'estere del 2-n,n,n,dimetil-alchil-amminoetanolo con acido acetico variamente sostituito e composizioni farmaceutiche che licontengono ad attivita' antiinfiammatoria e antisettica
IT1213579B (it) 1986-07-03 1989-12-20 Angelo Signor Marino Nicolini Flogistica. esteri di salsalato con guaiacolo atti al trattamento di broncopneumapatie a base
ZA882957B (en) 1987-04-27 1989-12-27 Syntex Pharma Int Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs
US5081118A (en) 1987-10-26 1992-01-14 Pfizer Inc. Benzothiazine dioxide derivatives
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
DK24089D0 (da) 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5100918A (en) 1989-05-25 1992-03-31 Sterling Drug, Inc. Prevention or treatment of sunburn using the S(+) isomer of ibuprofen
US5134165A (en) 1989-06-09 1992-07-28 Hirsch Kauffmann Dan J Method of treatment for loss of vision due to ophthalmic surgery
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5109011A (en) 1990-07-30 1992-04-28 Hoechst-Roussel Pharmaceuticals Incorporated P-acylaminophenoxycarbamates and derivatives
ES2023585A6 (es) * 1990-10-17 1992-01-16 Prodesfarma Sa Procedimiento de obtencion de aminoprofen.
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
DE69224294T2 (de) * 1991-10-16 1998-08-20 Richardson Vicks Inc Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
HRP921157A2 (en) 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5331000A (en) 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5190953A (en) 1992-03-26 1993-03-02 A. H. Robins Company, Incorporated Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
ES2046950B1 (es) 1992-06-08 1994-10-01 Menarini Lab Proceso para la produccion de acido s-(+)-2-(3-benzoilfenil)propionico por hidrolisis enantioselectiva catalizada enzimaticamente.
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
AU5342894A (en) 1992-10-30 1994-05-24 Merck Sharp & Dohme Limited Tachykinin antagonists
US5457051A (en) 1993-03-09 1995-10-10 Sepracor, Inc. Enantioselective hydrolysis of ketoprofen esters by beauveria bassiana and enzymes derived therefrom
PT693070E (pt) 1993-04-05 2002-12-31 Pharmaceutical Discovery Corp Pirido(2,3-b)(1,4)benzodiazepinonas como ligando do receptor m2 para o tratamento de desordens neurologicas
IT1264855B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
WO1995009590A1 (fr) 1993-10-07 1995-04-13 Odontex, Inc. Composes pour ameliorer l'absorption topique de formulations pharmaceutiques
DE4341628C2 (de) 1993-12-07 1996-05-30 Rehau Ag & Co Verfahren zur Herstellung von medizinischen Arbeitsmitteln
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5530145A (en) 1994-06-14 1996-06-25 Syn-Tech Chem & Pharm Co., Ltd. Anticholesteremic compounds
JPH10502102A (ja) 1994-06-14 1998-02-24 スミスクライン・ビーチャム・コーポレイション 固体合成用樹脂
JPH08208487A (ja) * 1995-02-01 1996-08-13 Sekisui Chem Co Ltd 炎症性皮膚疾患治療用外用剤
US5626838A (en) 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5570559A (en) 1995-09-26 1996-11-05 Lewis; Thomas D. Fall arrestor
US5902110A (en) 1995-12-18 1999-05-11 The Block Drug Company Bone regeneration
SE9600229D0 (sv) 1996-01-23 1996-01-23 Pharmacia Ab Novel potentiating agents
IT1282736B1 (it) 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
WO1997045113A1 (fr) 1996-05-30 1997-12-04 Sepracor Inc. Medicaments anti-inflammatoires non steroidiens pour la regulation du cycle de reproduction d'animaux domestiques
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
DE69828620T2 (de) * 1997-02-25 2005-12-01 The Regents Of The University Of Michigan, Ann Arbor Verfahren und zusammensetzungen zur vorbeugung und behandlung der chronologischer alterung der menschliches haut
DK0966277T3 (da) 1997-03-10 2006-03-27 Univ Loma Linda Med Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
AUPO612397A0 (en) 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
JP4181232B2 (ja) 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
KR19990026792A (ko) 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
GB9804861D0 (en) 1998-03-06 1998-04-29 Res Inst Medicine Chem Chemical compounds
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
DK1094781T3 (da) 1998-07-07 2008-11-03 Transdermal Technologies Inc Præparater til hurtig og ikke-irriterende transdermal administration af farmaceutisk aktive midler og fremgangsmåder til formulering af sådanne præparater samt administration deraf
US6277839B1 (en) * 1998-10-07 2001-08-21 Merck Frosst Canada & Co. Biphenylene lactams as prostaglandin receptor ligands
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6635674B1 (en) 1998-11-06 2003-10-21 Bristol-Myers Squibb Co. Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
AU2004201178A1 (en) 1999-02-26 2004-04-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IT1312088B1 (it) 1999-04-21 2002-04-04 Altergon Sa Cerotto per uso topico contenente eparina e diclofenac.
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
DE60028787T2 (de) * 1999-08-10 2007-06-06 Uab Research Foundation, Birmingham Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
WO2001054481A2 (fr) 2000-01-28 2001-08-02 Rohm And Haas Company Produits pharmaceutiques aux proprietes ameliorees
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
FR2808685B1 (fr) 2000-05-12 2004-10-08 Sanofi Synthelabo Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
DE10034802A1 (de) 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
US6416772B1 (en) 2001-01-12 2002-07-09 H. Wayne Van Engelen Topical dermal anaesthetic
US6528040B1 (en) 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
US6815359B2 (en) 2001-03-28 2004-11-09 Advanced Micro Devices, Inc. Process for improving the etch stability of ultra-thin photoresist
WO2002085297A2 (fr) 2001-04-24 2002-10-31 East Carolina University Compositions et formulations contenant un steroide non glucocorticoide et/ou un ubiquinone et kit destines au traitement des maladies respiratoires et pulmonaires
WO2003022270A1 (fr) 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Administration transcutanee d'un ester d'enalapril
US6805878B2 (en) * 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030143165A1 (en) 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
ITMI20021399A1 (it) 2002-06-25 2003-12-29 Nicox Sa Inibitori della cicloossigenasi 2
WO2004004648A2 (fr) 2002-07-03 2004-01-15 Nitromed, Inc. Composes anti-inflammatoires non-steroidiens nitroses, compositions et leur procede d'utilisation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
ES2436606T3 (es) 2003-03-12 2014-01-03 Celgene Corporation Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
CN1761462B (zh) 2003-03-18 2010-04-21 久光制药株式会社 含有非甾体类消炎镇痛剂的贴剂
ATE432087T1 (de) * 2003-03-21 2009-06-15 Nexmed Holdings Inc Antimykotischer nagellack und anwendungsverfahren
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
US7052715B2 (en) 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
BRPI0411347A (pt) 2003-06-10 2006-07-11 Pfizer combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
DE10335726A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener
JP4917255B2 (ja) * 2003-10-16 2012-04-18 第一三共ヘルスケア株式会社 サリチル酸類含有経口組成物
US8257780B2 (en) 2003-10-31 2012-09-04 Resource Development L.L.C. Therapeutic composition containing an organosilane quaternary compound and hydrogen peroxide for treating skin disorders and methods of using
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
JP3984283B2 (ja) 2004-01-05 2007-10-03 ニコックス,ソシエテ アノニム プロスタグランヂンニトロオキシ誘導体
JP2007531784A (ja) 2004-04-05 2007-11-08 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 活性物質組合せ物
WO2006076034A2 (fr) 2004-05-21 2006-07-20 Bhanu, Kalra Systeme a deux constituants stabilise pour le dosage par chimioluminescence dans des immunodiagnostics
ZA200700749B (en) * 2004-06-30 2008-09-25 Combinatorx Inc Methods and reagents for the treatment of metabolic disorders
TWI276687B (en) 2004-06-30 2007-03-21 Univ Nat Cheng Kung Method for kinetic resolution of alpha-substituted acids and esters thereof by using papaya lipases
NZ555362A (en) 2005-01-06 2009-05-31 Telik Inc Tripeptide and tetrapeptide thioethers
AU2006251989B2 (en) 2005-05-20 2010-05-27 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
CA2609618C (fr) * 2005-05-24 2016-01-05 Flamel Technologies Nouvelles formulations d'acide acetylsalicylique
US8354392B2 (en) 2005-07-06 2013-01-15 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
WO2008044095A1 (fr) 2006-10-11 2008-04-17 Techfields Biochem Co. Ltd Pro-médicaments d'oxicams solubles dans l'eau et chargés positivement et composés apparentés avec une vitesse de pénétration de la peau très élevée
EP2038251A4 (fr) * 2006-07-09 2010-04-21 Techfields Biochem Co Ltd Promédicaments hydrosolubles à charge positive de l'aspirine
CA2657636C (fr) 2006-07-18 2021-11-09 Techfields Biochem Co. Ltd Promedicaments d'ibuprofene hydrosolubles charges positivement ayant un taux de penetration cutanee tres rapide
ES2472545T3 (es) 2006-07-25 2014-07-01 Techfields Biochem Co. Ltd Profármacos de diclofenaco solubles en agua con carga positiva y con una tasa de penetración en piel muy rápida
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
CN101500984A (zh) * 2006-07-27 2009-08-05 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性酮洛芬及相关化合物的前药
HUE028425T2 (en) 2006-08-08 2016-12-28 Techfields Biochem Co Ltd Positive charged water-soluble prodrugs of aryl and heteroarylacetic acids with very fast skin penetration rate
US8458932B2 (en) 2006-08-11 2013-06-11 Alameda Technology, Llc Optical illusion device
JP5424880B2 (ja) * 2006-08-15 2014-02-26 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
WO2008026776A1 (fr) 2006-08-31 2008-03-06 Nanocarrier Co., Ltd. Composition transdermique, composition pharmaceutique transdermique et composition cosmétique transdermique comprenant un ingrédient actif encapsulant une micelle polymère
CN101506168B (zh) * 2006-09-03 2014-12-10 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药
JP5466006B2 (ja) * 2006-09-03 2014-04-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
AU2006349143B2 (en) * 2006-10-02 2013-07-18 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
CN101511774B (zh) 2006-10-03 2015-05-13 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药
WO2008056207A1 (fr) 2006-11-08 2008-05-15 Chongxi Yu Systèmes de libération transdermique de peptides et composés associés
ES2547258T3 (es) * 2006-12-10 2015-10-02 Chongxi Yu Sistemas de administración transdérmica de antibióticos beta-lactama
JP5826459B2 (ja) 2007-01-15 2015-12-02 チョンシー ユー 非常に高い皮膚浸透率を有するレチノイド及びレチノイド様化合物の正に荷電した水溶性プロドラッグ
WO2008093173A1 (fr) * 2007-01-31 2008-08-07 Chongxi Yu Promédicaments hydrosolubles à charge positive de 1h-imidazo[4, 5-c]quinolin-4-amines et composés associés à taux élevés de pénétration cutanée
WO2008110351A2 (fr) 2007-03-15 2008-09-18 Dompe' Pha.R.Ma S.P.A. Utilisation de dérivés d'acides -2-aryl-propioniques (r) et (s) en tant qu'agents antiseptiques;
KR20150058566A (ko) 2007-06-04 2015-05-28 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 nsaia 약물전구체 및 이들의 새로운 의약적 용도
AU2009219230A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection

Also Published As

Publication number Publication date
CA2745206C (fr) 2018-09-18
CN113636965A (zh) 2021-11-12
KR20210123406A (ko) 2021-10-13
CN111808011A (zh) 2020-10-23
RU2011127186A (ru) 2013-01-10
CN107320732B (zh) 2021-09-07
EP2370406A4 (fr) 2014-02-19
KR20200022525A (ko) 2020-03-03
AU2009322112A1 (en) 2010-06-10
RU2017130909A (ru) 2019-02-05
WO2010065936A1 (fr) 2010-06-10
AU2009322112B2 (en) 2016-12-15
MX2011005920A (es) 2011-06-20
CN107320732A (zh) 2017-11-07
JP2017025109A (ja) 2017-02-02
KR20230085223A (ko) 2023-06-13
MX2019002308A (es) 2019-07-08
KR101946297B1 (ko) 2019-02-11
KR102225999B1 (ko) 2021-03-10
CA3013497C (fr) 2023-10-31
KR20170078863A (ko) 2017-07-07
CN108191846B (zh) 2021-08-20
CA2745206A1 (fr) 2010-06-10
MX337730B (es) 2016-03-16
JP6670223B2 (ja) 2020-03-18
CN107261149A (zh) 2017-10-20
BRPI0922263B1 (pt) 2021-08-31
US20230233516A1 (en) 2023-07-27
CN111808011B (zh) 2024-02-27
KR101753296B1 (ko) 2017-07-03
TW201031423A (en) 2010-09-01
KR20180103109A (ko) 2018-09-18
MX2021000588A (es) 2022-06-08
BRPI0922263A2 (pt) 2020-09-01
US11541029B2 (en) 2023-01-03
JP2018188472A (ja) 2018-11-29
CN102307857A (zh) 2012-01-04
JP2015205912A (ja) 2015-11-19
RU2017130909A3 (fr) 2019-02-05
US20110269689A1 (en) 2011-11-03
JP2019089833A (ja) 2019-06-13
RU2765463C2 (ru) 2022-01-31
JP2012511027A (ja) 2012-05-17
AU2017201227A1 (en) 2017-03-16
CN108191846A (zh) 2018-06-22
EP2370406A1 (fr) 2011-10-05
JP2017036327A (ja) 2017-02-16
CA3213470A1 (fr) 2010-06-10
TWI383802B (zh) 2013-02-01
JP6793215B2 (ja) 2020-12-02
RU2630577C2 (ru) 2017-09-11
KR20110098933A (ko) 2011-09-02
BR122021011394B1 (pt) 2021-09-28
MX362949B (es) 2019-02-27

Similar Documents

Publication Publication Date Title
US20230233516A1 (en) High penetration compositions and their applications
US20210353579A1 (en) High penetration compositions and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807

EEER Examination request

Effective date: 20180807